Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes

Correction to: Pharmacoeconomics 2012; 30(11): 1067–1084 https://doi.org/10.2165/11595080-000000000-00000

Unfortunately, the article’s Supplementary File Link is not working and the ESM material is missing from the published article. The correct version is updated here.

Author information

Correspondence to Laura Panattoni.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 249 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Panattoni, L., Brown, P.M., Ao, B.T. et al. Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes. PharmacoEconomics 38, 315 (2020). https://doi.org/10.1007/s40273-020-00885-8

Download citation